954114-92-2

Upstream product

• 149777-72-0 4-Bromo-2-methoxy-1-<(tert-butyldimethylsilyl)oxy>benzene 
• 2426-87-1 3-methoxy-4-(phenylmethoxy)benzaldehyde 
• 954114-85-3 (4R,5S)-5-(4-(benzyloxy)-3-methoxyphenyl)-4-methyldihydrofuran-2(3H)-one 
• 954114-84-2 C₂₅H₃₅O₃SiN 
• 954114-83-1 (2R,3S)-3-(4-(benzyloxy)-3-methoxyphenyl)-3-((tert-butyldimethylsilyl)oxy)-2-methylpropan-1-ol 
• 954114-82-0 C₃₀H₄₃NO₆Si 
• 954114-81-9 C₂₄H₂₉NO₆ 
• 954114-87-5 C₃₃H₄₄O₆Si 
• 954114-86-4 (3R,4R,5S)-5-(4-(benzyloxy)-3-methoxyphenyl)-3,4-dimethyldihydrofuran-2(3H)-one 
• 954114-88-6 C₃₃H₄₄O₆Si 

Downstream Products

• 112652-46-7 (+)-fragransin A₂ 

Relevant academic research and scientific papers

MANASSANTIN COMPOUNDS AND METHODS OF MAKING AND USING SAME

Provided are manassantin compounds and methods of using the compounds. Provided are methods of treating a disease, the method comprising administering a compound according to Formula I. Further provided are pharmaceutical compositions comprising compounds

Analysis of HIF-1 inhibition by manassantin A and analogues with modified tetrahydrofuran configurations

We have shown that manassantin A downregulated the HIF-1α expression and inhibited the secretion of VEGF. We have also demonstrated that the 2,3-cis-3,4-trans-4,5-cis-configuration of the tetrahydrofuran is critical to the HIF-1 inhibition of manassantin

Stereoselective synthesis of tetrahydrofuran lignans via BF 3·OEt2-promoted reductive deoxygenation/ epimerization of cyclic hemiketal: Synthesis of (-)-odoratisol C, (-)-futokadsurin A, (-)-veraguensin, (+)-fragransin A2, (+)-galbel

A versatile route to the synthesis of 2,5-diaryl-3,4- dimethyltetrahydrofuran lignans, (-)-odoratisol C. (1), (-)-futokadsurin A (2), (-)-veraguensln (3), (+)-fragransin A2 (4), (+)-galbelgin (5), and (+)-talaumidin (6), is described. Central t